CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 63 enrolled
Drug / intervention
Dupilumab +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05878093
NCT05878093Phase 3Completed

A Randomized, Double-blind, Placebo-controlled Efficacy and Safety Study of Dupilumab, in Chinese Adult Participants With Chronic Rhinosinusitis With Nasal Polyposis (CRSwNP) on a Background Therapy With Intranasal Corticosteroids

Sanofi·interventional·Posted May 26, 2023·Updated Sep 25, 2025

In Brief

A Phase 3 clinical trial evaluating Dupilumab, Placebo, and 1 other intervention for Chronic Rhinosinusitis With Nasal Polyps. Completed, enrolled 63 participants across 18 sites.

Detailed Summary

This is a parallel group, Phase 3, 2-arm study for treatment. The purpose of this study is to evaluate dupilumab subcutaneous (SC) injections compared to placebo in Chinese adult participants with CRSwNP, on a background therapy with intranasal corticosteroids (budesonide nasal spray). Study details include: * The study duration will be up to 40 weeks. * The treatment duration will be up to 24 weeks. * The number of visits will be 7.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesChina
Collaborators--

Timeline

Phase 3CompletedFinished
202420252026
First PostedMay 26, 2023
Enrollment StartMay 16, 2023
Primary CompletionSep 6, 2024
Study CompletionNov 28, 2024
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 3.1 years ago

Interventions

Dupilumabdrug

solution for subcutaneous injection

Placebodrug

solution for subcutaneous injection

Budesonidedrug

nasal spray (suspension)